Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05737940). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 260 participants (ACTUAL). Conditions: Pulmonary Hypertension (World Health Organization Group 2), Heart Failure. Interventions: DRUG: AZD3427; DRUG: Placebo. Primary outcome measures: Change From Baseline in Pulmonary Vascular Resistance (PVR) , Baseline to Week 25. Brief summary: This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2